Previous work has demonstrated the capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations. The data in these studies support the hypothesis that capsular polysaccharide plays at least some role in the specificity of the protection conferred by ribosomal preparations. In this investigation, the presence of capsular polysaccharide and lipopolysaccharide in K. pneumoniae ribosomal preparations was demonstrated by using immunodiffusion tests. Lipopolysaccharide content was determined for mice treated with actinomycin D. The serotype of 0 antigen did not play a role in the orientation of the specificity of the protection. The possibility that lipopolysaccharide might act as an adjuvant was not unlikely since the ribosomal preparations which contained the greatest amounts of lipopolysaccharide appeared to be the most immunoprotective preparations. Ribosomal preparations extracted from a noncapsulated mutant of K. pneumoniae did not protect mice. This finding suggested that capsular polysaccharide might play a role in the immunoprotective activity of ribosomes. This hypothesis was tested by using K. pneumoniae K2 bacteriophage-associated-glycanase, which specifically hydrolyzed K. pneumoniae K2 capsular polysaccharide and thereby suppressed the immunoprotective activity of K. pneumoniae K2 ribosomal preparations. In contrast, the K2 bacteriophage-associated glycanase did not interfere with the immunoprotective activity of K. pneumoniae Kl ribosomal preparations. These results clearly demonstrate that capsular polysaccharide, which is an extraribosomal antigen, is involved in the immunoprotective activity of K. pneumoniae ribosomal preparations.
Youmans and Youmans (45, 46) first reported that vaccination with ribosomes extracted from mycobacteria protected mice against infection with virulent Mycobacterium tuberculosis. Since then, immunogens of similar origins have been derived from various microorganisms (3-5, 8-10, 13-17, 19-24, 26-29, 33, 34, 3642, 44) . However, although the immunoprotective activity of ribosomal preparations has been well established, there is considerable controversy in the literature concerning the immunogenic principle of these ribosomal preparations. Workers have presented evidence suggesting that ribosomal ribonucleic acid (13, 42) or proteins (17, 27, 36) may be responsible for the protection associated with ribosomal vaccines. Other experiments have shown that ribosomal preparations have been contaminated with cell surface material (4, 22, 28) . It has been reported that 0 antigen contaminates ribosomal preparations and can contribute to the protection afforded by these vaccines (8, 9, 24) . In a previous article (33) , we presented data demonstrating the cap-71 sular serotypic specificity of the protection conferred on mice by K. pneumoniae ribosomal preparations. The results ofthis study supported the hypothesis that capsular polysaccharide (CP) plays at least some role in the orientation of the specificity induced by ribosomal preparations. However, these results did not provide direct evidence for the involvement of CP in the immunoprotective activity of K. pneumoniae ribosomal preparations.
In the present paper we report the results of a study on the immunoprotective activity of K. pneumoniae Kl and K2 ribosomal preparations before and after degradation with K2 bacteriophage-associated glycanase, which specifically hydrolyzes K. pneumoniae K2 capsular polysaccharide. The specific suppression of the immunoprotective activity of K. pneumoniae K2 ribosomal preparations was demonstrated, whereas the immunoprotective activity of K. pneumoniae Kl ribosomal preparations remained unaffected. This finding provides direct evidence that CP is involved in the immunopro- A noncapsulated mutant of K. pneumoniae 52-145 (O1:K-) was selected by culture in the presence of K. pneumoniae K2 bacteriophage. This mutant was avirulent for mice at a dose of 5 x 106 colony-forming units per mouse.
Bacteriophage strain. The bacteriophage used was K. pneumoniae K2 bacteriophage, which was isolated originally from Freiburg sewage and was kindly supplied by H. Geyer, Zentrum fur Biochemie am Klinikum der Justus-Liebig-Universitat, Lahn-Giessen, West Germany. This K. pneumoniae K2 bacteriophage carries an enzymatic activity which cleaves the K2 CP at the fi-glucose-(1-4)-mannose linkages ( Fig.   1 ), giving rise to a series of mono-, di-, and oligomeric repeating unit split products (12) .
Growth of bacteria. Each lyophilized bacterial strain was inoculated into a 10-ml tube, transferred to a 500-ml flask, and finally transferred to a 5,000-ml flask containing nutrient broth (Institut Pasteur production no. 64-067). The flasks were incubated at 370C for 12 to 15 h without agitation, and the bacterial cells were harvested by continuous-flow centrifugation at 40,000 x g at 40C.
Extraction of CRP. Crude ribosomal preparation (CRP) were prepared by a slight modification of the method of Schalla and Johnson (34 40 ,000 lb/in2. Sodium dodecyl sulfate (0.5%, wt/vol) was added, and then NH4Cl was added to a final concentration of 0.35 M. The extract was centrifuged at 25,000 x g for 20 min to remove cellular debris and intact cells. A 21-g amount of dry (NH4)2S04 was added to 100 ml of the supernatant fluid with gentle stirring for 3 min. The slurry was centrifuged at 25,000 x g for 20 min, and the pellet was discarded. An additional 21 g of dry (NH4)2SO4 was added to the supernatant fluid with gentle stirring for 3 min. The slurry was centrifuged at 25,000 x g for 20 min, and the supernatant fluid (SF,) was saved. The precipitate was suspended in TMN and centrifuged at 25,000 x g for 20 min.
The supernatant fluid from this last centrifugation was combined with SF, and centrifuged at 150,000 x g for 3 h. The pellet was suspended in TMN, dialyzed for 48 h against several changes of TMN, and centrifuged at 150,000 x g for 2 h. The final CRP was suspended in TMN and stored in small volumes at -200C. Extraction of LPS. Lipopolysaccharide (LPS) was prepared from the noncapsulated mutant of K. pneumoniae 52-145 (O1:K-) by the phenol-water procedure of Westphal and Jann (43) .
Isolation of CP. CPs were prepared by the method of Joseleau et al. (18); 7 g of packed cells and mucus was harvested and diluted with 100 ml of water containing 1% phenol. After 24 h at 4°C, the suspension was centrifuged for 1 h at 100,000 x g. The clear supernatant solution was concentrated in a rotary evaporator to 30 ml, poured into 150 ml of ethanol, and centrifuged for 30 min at 30,000 x g. The crude polysaccharide pellet was dissolved, precipitated with 3% Cetavlon, dissolved in 50 ml of 2 M sodium chloride, and precipitated with 300 ml of ethanol. The purified polysaccharide was then dissolved in 100 ml of distilled water, deionized on Amberlite IR-120 (H') resin, dialyzed, and freeze-dried.
Bacteriophage stocks. High-titer bacteriophage stocks were prepared by the agar layer method of Swanstrom and Adams (35) , as modified by Adams and Park (1). Briefly, 2.5 ml of melted 0.7% nutrient agar was inoculated with 0.2 ml of broth containing 108 bacteria and 104 phage particles and then was poured onto plates of hardened 1.5% nutrient agar. After agar solidification, the plates were incubated overnight at 37°C. Then, 3 ml of broth and a few drops of chloroform were added to each plate, and the agar layer was scraped off with a sterile glass rod into a centrifuge tube.
The broth and agar were shaken vigorously and centrifuged at 2,000 x g. The supernatant containing the phage was preserved and stored over chloroform at 40C.
Phage titration. Phage titration was performed by Immunization and challenge. Mice were immunized subcutaneously with 0.5 ml of the vaccine preparation diluted in sterile pyrogen-free saline without adjuvant. Immunizing doses of ribosomal preparations were calculated on the basis of protein content. Controls were inoculated subcutaneously with 0.5 ml of sterile pyrogen-free saline.
All mice were challenged intraperitoneally with 100 LDso of K. pneumoniae. The bacterial count at the time of challenge was confirmed by the spread plaque technique. Deaths, which occurred principally within 8 days after challenge, were recorded 14 days after challenge; 50% protective doses (PD50) were calculated by the Reed-Muench formula (31) .
RESULTS
Chemical studies. Chemical assays of the CRP indicated that the ratio of ribonucleic acid to protein ranged from about 0.8 to 2. The ratio of absorbance at 260 mu to absorbance at 280 mu was between 1.5 and 1.8. The protein content of the CRP varied from about 35 to 48% of the dry weight. K. pneumoniae 52-145 CRP contained 10% LPS, and K. pneumoniae A-215 and 7825 CRP contained 2% LPS. CP contained 6% protein and 1% LPS. LPS contained less than 0.5% protein.
Identification of CP in CRP. Immunochemical testing with rabbit antiserum against strain A-215 (O1:Kl) CRP showed partial cross-reactivity between Kl CP and strain A-215 (O1:K2) CRP (Fig. 2A) . Similarly, K2 CP and strain 52-145 (01:K2) CRP showed partial cross-reactivity with antiseumn against strain 52-145 (O1:K2) CRP (Fig. 2B) . The patterns obtained indicated that the CRP contained contaminant CP.
Identification of LPS in CRP. The immunodiffusion pattern in Fig. 2C pressed as protein content of ribosomes) of CRP extracted from K. pneumoniae 52-145 (O1:K2), and three other groups were immunized with 2 to 50 ,ug of CRP extracted from the K. pneumoniae 52-145 (O1:K-) noncapsulated mutant. One control group received saline. All animals were challenged 14 days later with 100 LD50 of K. pneumoniae 52-145 (O1:K2). Table 1 shows the survival on day 14 after challenge and the PD50. As with Formalin-treated cells, the immunoprotective activity of the CRP extracted from the noncapsulated mutant (PD5o, 25 ,ug) 
DISCUSSION
We showed in a previous paper (33) that the active immunity and the passive immunity induced in mice by K. pneumoniae ribosomal preparations were specific for the capsular serotype of the original strain. These results suggested that the ribosomal preparations were contaminated by CP and prompted us to investigate the possible presence of CP in our ribosomal preparations. In this paper we present direct On the other hand, contaminating LPS has been observed frequently in ribosomal preparations extracted from Escherichia coli (6), Pseudomonas aeruginosa (13, 22) , and Salmonella typhimurium (8, 9, 15, 26) . Therefore, the presence of LPS in our K. pneumoniae ribosomal preparations was not surprising. However, the presence of an extraribosomal antigen (for example, CP or LPS) in ribosomal preparations is not, by itself, direct evidence that the contaminating antigen contributes to the immunoprotective activity of the ribosomal preparations. Eisenstein (8) suggested that the protective capacity of S. typhimurium ribosomes might be due to contaminating 0 antigen; in this study Eisenstein used genetically defined strains of S. typhimurium which were unable to make 0 antigens. Lin and Berry (24) reported similar results; they used mutant S. typhimurium LT2-Ml strains, which lack uridine-diphosphate-Dgalactose epimerase. All of these results suggested that LPS participates in the immunoprotective activities of ribosomal vaccines, but they did not furnish direct evidence for this contention because the experiments did not eliminate the possibility that there was variation in characters other than LPS structure in the different mutant strains used. We were faced with the same problem, namely, the interpretation of our results, which were obtained with either whole cells or CRP extracted from the noncapsulated mutant of K. pneumoniae. The inability of these preparations to protect mice supported a role for CP but was not direct evidence for it. Indeed, these experiments did not eliminate the possibility of variation in characters other than the presence or absence of CP.
The lack of cross-protection between K. pneumoniae (Ol:K1) 7825 or A-215 CRP and K. pneumoniae (O1:K2) 52-145 CRP (33) indicated that the specificity of the protection did not depend upon the 0-antigen specificity. However, these results did not rule out a possible contribution of the LPS as an adjuvant for the immunoprotective activity of the ribosomal preparations. The greater activity of K. pneumoniae 52-145 CRP compared with the activity of K. pneumoniae A-215 CRP, as well as the highest content of contaminating LPS in strain 52-145 CRP, supported this hypothesis, which was in keeping with the results of Hoops et al. (15) with S. typhimurium ribosomes.
The identification of cell surface proteins in S. typhimurium ribosomal preparations by Misfeldt and Johnson (28) did confirm the presence of extraribosomal antigens in ribosomal preparations, but it did not prove that the immunoprotective antigens are these extraribosomal antigens.
The specificity of the protection, the identification of CP in ribosomal preparations, and the inability of ribosomal preparations extracted from a noncapsulated mutant to protect mice support the hypothesis that an extraribosomal antigen (CP) is involved in the immunoprotective activity of K. pneumoniae ribosomal preparations, but these findings do not prove this hypothesis.
Only the experiments with K2 bacteriophage demonstrated beyond doubt that CP participates in the immunoprotective activity of ribosomal preparations. To our knowledge, this is the first time that anyone has provided direct evidence concerning the involvement of an extraribosomal antigen in the immunoprotective activity of a ribosomal vaccine.
In preliminary experiments we found that purified CP did not protect mice (unpublished data). We propose the following two hypotheses to explain this apparent contradiction of the above-described demonstration of involvement of CP in the immunoprotective activity of K. pneumoniae ribosomes.
(i) The immunogenicity of CP is due to its association with ribosomal ribonucleic acid, which may act as an adjuvant or a carrier for this polysaccharide in the same way that Youmans and Youmans (47) showed ribonucleic acid to be an adjuvant for bovine y-globulin. However, an in vitro mixture of CP with ribosomal preparations extracted from the noncapsulated (K-) K. pneumoniae mutant did not protect mice in preliminary experiments (unpublished data).
(ii) The CP present in ribosomal preparations is associated with outer membranous vesicles which copurify with ribosomes. These membranous vesicles contain LPS, protein, and lipids, which may render CP immunoprotective. This hypothesis is in agreement with the results of Jensen et al. (16) , who obtained from Vibrio cholerae ribosomal preparations an immunoprotective fractions containing protein, lipid, and carbohydrate but not ribonucleic acid.
We are presently studying this second hypothesis by isolating such an immunoprotective antigen from K. pneumoniae cell surfaces and comparing the immunoprotective activity of this antigen with that of ribosomal preparations.
